Cargando…
A novel strategy for modulation of MDSC to enhance cancer immunotherapy
Myeloid derived suppressor cells (MDSC) suppress anti-tumor immune responses. Our recent publication provides evidence that SHIP-1 plays a prominent role in pancreatic tumor development by regulating MDSC. Therefore, SHIP-1 may be a potential therapeutic target for the treatment of MDSC-related hema...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489768/ https://www.ncbi.nlm.nih.gov/pubmed/23162780 http://dx.doi.org/10.4161/onci.20201 |
| _version_ | 1782248778729783296 |
|---|---|
| author | Ghansah, Tomar |
| author_facet | Ghansah, Tomar |
| author_sort | Ghansah, Tomar |
| collection | PubMed |
| description | Myeloid derived suppressor cells (MDSC) suppress anti-tumor immune responses. Our recent publication provides evidence that SHIP-1 plays a prominent role in pancreatic tumor development by regulating MDSC. Therefore, SHIP-1 may be a potential therapeutic target for the treatment of MDSC-related hematological malignancies and solid tumors. |
| format | Online Article Text |
| id | pubmed-3489768 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | Landes Bioscience |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-34897682012-11-16 A novel strategy for modulation of MDSC to enhance cancer immunotherapy Ghansah, Tomar Oncoimmunology Author's View Myeloid derived suppressor cells (MDSC) suppress anti-tumor immune responses. Our recent publication provides evidence that SHIP-1 plays a prominent role in pancreatic tumor development by regulating MDSC. Therefore, SHIP-1 may be a potential therapeutic target for the treatment of MDSC-related hematological malignancies and solid tumors. Landes Bioscience 2012-09-01 /pmc/articles/PMC3489768/ /pubmed/23162780 http://dx.doi.org/10.4161/onci.20201 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| spellingShingle | Author's View Ghansah, Tomar A novel strategy for modulation of MDSC to enhance cancer immunotherapy |
| title | A novel strategy for modulation of MDSC to enhance cancer immunotherapy |
| title_full | A novel strategy for modulation of MDSC to enhance cancer immunotherapy |
| title_fullStr | A novel strategy for modulation of MDSC to enhance cancer immunotherapy |
| title_full_unstemmed | A novel strategy for modulation of MDSC to enhance cancer immunotherapy |
| title_short | A novel strategy for modulation of MDSC to enhance cancer immunotherapy |
| title_sort | novel strategy for modulation of mdsc to enhance cancer immunotherapy |
| topic | Author's View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489768/ https://www.ncbi.nlm.nih.gov/pubmed/23162780 http://dx.doi.org/10.4161/onci.20201 |
| work_keys_str_mv | AT ghansahtomar anovelstrategyformodulationofmdsctoenhancecancerimmunotherapy AT ghansahtomar novelstrategyformodulationofmdsctoenhancecancerimmunotherapy |